I want every cancer patient in the world to understand how stereotactic radiotherapy (SABR) can help them live longer and live better in their fight against cancer.
Radiotherapy kills cancer cells where ever it is targeted. The higher the radiotherapy dose the greater the chance of killing every last cancer cell. But higher doses can also damage normal cells. This is an issue with all cancer treatments. Surgeons have to cut through and damage or remove normal healthy cells before they get to tumours. Cancer drugs, even if they are targeted or using your own immune system (immunotherapy) travel throughout your body and cause side effects when they damage normal cells.
A/Prof Senthi was a co-author of the landmark SABR-COMET clinical trial, published in The Lancet.
This internationally recognised study demonstrated that carefully selected patients with a limited number of metastatic cancers may live significantly longer when all known cancer deposits are treated with stereotactic ablative radiotherapy (SABR), compared with standard treatment alone.
The findings helped establish the concept of treating oligometastatic cancer with curative intent and have influenced cancer care internationally.
Modern radiotherapy can target tumours with remarkable accuracy while minimising radiation to surrounding healthy tissues.
A/Prof Senthi’s research has focused on advancing stereotactic radiotherapy (SABR/SBRT and stereotactic radiosurgery)—highly precise treatments that allow many patients to receive fewer treatment sessions while maintaining excellent cancer control.
Click here to read more about A/Prof Senthi’s research as well as some general information on the main radiotherapy treatment options.
